Drug Profile
INCB 59872
Alternative Names: INCB 059872; INCB59872Latest Information Update: 31 Oct 2021
Price :
$50
*
At a glance
- Originator Incyte Corporation
- Class Antianaemics; Antineoplastics; Small molecules
- Mechanism of Action Lysine specific demethylase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer; Ewing's sarcoma; Prostate cancer; Sickle cell anaemia
Most Recent Events
- 10 Apr 2021 Data from preclinical studies in Acute myeloid leukaemia models presented at 112th Annual Meeting of the American Association for Cancer Research (AACR-2021)
- 04 Aug 2020 Discontinued - Phase-I for Ewing's Sarcoma (In adolescents, In children, In the elderly, Second-line therapy or greater, In adults) in Italy, United Kingdom, Spain, USA (PO)
- 04 Aug 2020 Discontinued - Phase-I/II for Cancer (Late-stage disease) in Netherlands, Belgium, USA (PO)